Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Challenges of creating a patient-specific DNA assay

Michail Ignatiadis • 25 Nov 2021
SABCS 2021
Breast Cancer

Michail Ignatiadis, MD, PhD, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium, talks on challenges associated with creating patient-specific DNA assays, including access to tumor DNA. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Disclosures

Novartis, Invited Speaker and Advisory Board, Personal

Seattle Genetics, Other, Personal,

Independent monitoring committee Natera, Coordinating PI, Institutional, No financial interest

Pfizer, Coordinating PI, Institutional, Financial interest

Roche, Coordinating PI, Institutional, Financial interest

More from Michail Ignatiadis

TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer
2:15
TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer
Michail Ignatiadis • 14 Sep 2024
Clinical applications of liquid biopsy in metastatic breast cancer
1:17
Clinical applications of liquid biopsy in metastatic breast cancer
Michail Ignatiadis • 14 Sep 2024
Challenges in liquid biopsy implementation for metastatic cancer
0:58
Challenges in liquid biopsy implementation for metastatic cancer
Michail Ignatiadis • 14 Sep 2024
Facilitating translational research in clinical trials
3:29
Facilitating translational research in clinical trials
Michail Ignatiadis • 14 Mar 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals